Stock Analysts’ updated eps estimates for Tuesday, August 22nd:

FIG Partners initiated coverage on shares of BayCom Corp (NASDAQ:BCML). The firm issued an outperform rating on the stock.

Brookfield Infrastructure Partners (NYSE:BIP) (TSE:BIP.UN) was downgraded by analysts at BMO Capital Markets from an outperform rating to a neutral rating. The firm currently has $44.00 price target on the stock.

Brookfield Infrastructure Partners L.P. (TSE:BIP.UN) (NYSE:BIP) was downgraded by analysts at BMO Capital Markets from an outperform rating to a neutral rating. They currently have C$55.00 target price on the stock.

Cominar REIT (TSE:CUF.UN) was upgraded by analysts at Eight Capital from a neutral rating to a buy rating.

Dollar Tree (NASDAQ:DLTR) had its hold rating reaffirmed by analysts at Piper Jaffray Companies. The firm currently has a $85.00 price target on the stock.

Entellus Medical (NASDAQ:ENTL) had its buy rating reaffirmed by analysts at Piper Jaffray Companies. The firm currently has a $21.00 price target on the stock.

Ensign Energy Services (TSE:ESI) was downgraded by analysts at Raymond James Financial, Inc. from an outperform rating to a market perform rating. They currently have C$7.20 target price on the stock, down from their previous target price of C$9.00.

Premier (NASDAQ:PINC) had its hold rating reiterated by analysts at Piper Jaffray Companies.

TRANSAT AT (TSE:TRZ) was upgraded by analysts at National Bank Financial from a sector perform rating to an outperform rating. National Bank Financial currently has C$12.00 target price on the stock, up from their previous target price of C$8.50.

TRANSAT AT (TSE:TRZ) was upgraded by analysts at Laurentian from a hold rating to a buy rating. They currently have C$10.25 target price on the stock.

TRANSAT AT (TSE:TRZ) was upgraded by analysts at Laurentian Bank of Canada from a hold rating to a buy rating. The firm currently has C$10.25 target price on the stock.

Workday (NYSE:WDAY) had its buy rating reiterated by analysts at Piper Jaffray Companies. The firm currently has a $115.00 price target on the stock.

Intersect ENT (NASDAQ:XENT) had its buy rating reissued by analysts at Piper Jaffray Companies. The firm currently has a $35.00 price target on the stock.